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It has been now twenty years since the first description of induced sputum as a research application in asthma [1, 
2]. Since then the research application of this technique has really exploded giving rise to an impressive number 
of publications in the field of asthma and COPD. Overall it is fair to say that asthma is rather an eosinophilic 
airway disease while COPD patients usually exhibit a massive neutrophilic inflammation [3]. This view is 
however simplistic and when asthma becomes more severe, eosinophilic inflammation usually coexists with 
neutrophilic inflammation [4, 5]. On the other hand, a not negligible contingent of COPD displays an 
eosinophilic airway inflammation [6]. 
A lot of studies have measured biochemical compounds in sputum supernatant associated with eosinophilic and 
neutrophilic inflammation. All these studies can be somehow summarized by saying that eosinophilic airway 
inflammation is usually associated with raised secretion products from eosinophils like eosinophil cationic 
prtotein (ECP) and Th2 cytokines like interleukine-5, while neutrophilic inflammation is rather associated with 
secretion products from neutrophils like myeloperoxidase and the neutrophilic chemokine interleukine-8 [7]. 
Recent studies have gone further by unravelling the sputum cell gene expression associated with each type of 
inflammation [8, 9]. 
Sputum has also made it possible to undertake elegant mechanistic studies looking at cellular pharmacology or at 
biological properties of supernatant. As an example sputum cells can be cultured for 24h ex vivo and assessed 
for their capacity to release cytokine or growth factors [10]. Also the fluid phase was shown to contain 
chemotactic or anti-apoptotic activity for eosinophils or neutrophils that sometimes correlated to disease severity 
[11-14]. 
One of the most important features in COPD and severe asthma is the airway and lung remodelling, the latter 
being essentially seen in COPD. By definition remodelling is measured on piece of tissues usually obtained by 
bronchial biopsies performed during a bronchoscopy. Alternatively re-modelling is more and more assessed by 
fine lung imaging like thin slice chest CT. There has been early attempt to validate some biochemical 
compounds from sputum supernatant as markers of airway remodelling. Matrix metalloproteases (MMPs) and 
their physiological inhibitors (TIMPs) are keys in regulating the metabolism of conjunctive tissue. Among those 
proteins emphasis has been placed on MMP-9, a matrix metalloprotease with gelatinolytic activity, and TIMP-1, 
its physiological inhibitor. Both the pro and the activated form of MMP-9 and TIMP-1 were found to be raised in 
asthmatics and COPD as compared to healthy subjects [15]. Vignola et al. have shown the ratio MMP-9/TIMP-1 
to be related airway calibre assessed by FEV1 [16]. In stable asthmatics and patients suffering from chronic 
bronchitis they showed that the lower the ratio the lower the FEV1 suggesting that an excess of TIMP-1 would 
favour tissues remodelling [17]. In this issue of the journal Dar et al. confirmed previous results of Vignola et al. 
by showing raised sputum levels of MMP-9 and TIMP-1 in sputum from asthmatics and COPD but a clearly 
reduced ratio MMP-9/TIMP-1 when disease severity increases [18]. Their study is a further validation of the 
utility of this ratio as a marker of airway remodelling since they found a relationship between the progression of 
the remodelling on chest CT and a low ratio value. 
Conversely high MMP-9/TIMP-1 ratio has been found in acute asthma [19] and following experimental 
allergenic exposure [20]. This suggests that flare up of airway inflammation is actually associated with an 
enhanced local gelatinolytic activity. Thus the picture may be different in acute conditions as opposed to the 
stable state of severe chronic disease. Whether a low MMP-9/TIMP-1 ratio would be predictive of an accelerated 
lung decline in asthma and COPD is an interesting question that should be addressed in a prospective 
longitudinal study. 
Induced sputum has been instrumental in the development of asthma and COPD phenotypes based on the nature 
of the airway cellular inflammation [21, 22]. Based on our experience in a large cohort of asthmatic patients it 
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appears that paucigranulocytic and eosinophilic (> 3%) asthma are the two most frequent phenotypes each 
accounting for approximately 40% of patients while neutrophilic (> 76%) asthma only represents roughly 15-
16% of asthmatics and mixed granulocytic was rather rare (< 5%). In contrast the dominant pattern in COPD is 
the neutrophilic pattern [23, 24] even if a small fraction of COPD exhibits eosinophilic inflammation associated 
with sign of mast cell activation reminiscent of asthma pathophysiology [25]. The nature of the cellular 
inflammation is likely to depend on the stimuli involved, allergens being the most conspicuous factor for 
eosinophilic inflammation whereas neutrophilic inflammation is most frequently induced by infection or 
pollutant exposure [26]. Interestingly targeting the extent of eosinophilic inflammation by adjusting the dose of 
inhaled or systemic corticoids was shown to improve asthma [27, 28] or COPD [29] control by reducing the 
number of exacerbations. By contrast the neutrophilic inflammation in asthma or COPD is rather insensitive to 
corticoids but may be attenuated by regular intake of macrolides [30]. 
Induced sputum has been shown to be a valid method to collect cells during asthma [31] and COPD [32-34] 
exacerbations. Most of the time, this disease state is associated with an amplification of the baseline 
inflammatory process. Not surprisingly flares up of eosinophilic or neutrophilic inflammation have been reported 
in several studies. The nature of the inflammation is more dependent of the etiologic agent causing the 
exacerbation than of the disease itself. However, it was reported that some agents such as viruses may cause both 
types of inflammation [32]. In this issue of the journal Zanini A. et al. report on the case of one COPD stage III 
successively developing two exacerbations featuring a heavily neutrophilic inflammation in the first case and a 
moderate sputum eosinophilia in the second one [35]. In both cases the patient recovered after treatment but 
interestingly the authors adapted their treatment strategy according to the sputum cellular profile. Assuming an 
infectious origin in the first case they prescribed antibiotics without corticoids when sputum was neutrophilic 
while they choose to go for a course of systemic corticoids when sputum analysis revealed high eosinophil 
counts. The origin of the flare up of sputum eosinophilia in COPD is unclear and there was no history of allergy 
in the present case. Virus infection was a plausible cause. Eosinophilic inflammation in acute exacerbation of 
chronic bronchitis was already reported almost twenty years ago [36]. It is thus important to realize that 
exacerbations of COPD are not always neutrophilic and that raised eosinophilia may justify a course of systemic 
corticoids perhaps not indicated when inflammation is purely neutrophilic. Whether corticoids are really useless 
when inflammation is heavily neutrophilic and antibiotics useless when inflammation is strongly eosinophilic, is 
a key issue. Although case reports are of great values in generating hypotheses there is a need to undertake 
prospective studies to definitely answer this crucial question. Until we have the response it is probably careful to 
combine systemic corticoids and antibiotics to treat exacerbations of severe COPD. 
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